Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
- PMID: 31933238
- DOI: 10.1007/s40290-019-00305-z
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
Abstract
Nonalcoholic fatty liver disease (NAFLD) has now become a worldwide health issue due to the obesity epidemic, affecting approximately 90% of the obese population and 15-40% of the general population. It is the most common form of chronic liver disease in the United States. NAFLD constitutes a spectrum of diseases ranging in severity from mild, such as fatty liver, progressing into nonalcoholic steatohepatitis (NASH), then fibrosis, and ending with cirrhosis. NASH and increasing fibrosis stage are associated with increased morbidity and mortality; the fibrosis stage is therefore a critical element of risk stratification needed to determine therapeutic approach and also the response to treatment. Liver biopsy is considered the 'gold standard' in the diagnosis of NAFLD. However, it is not practical for widespread clinical use because it is invasive, costly, and associated with complications including occasional death. These limitations have driven the development of noninvasive tests that can accurately predict the fibrosis stage in those with NAFLD. In this review, we provide a concise overview of different non-invasive measurements used for NAFLD/NASH.
Similar articles
-
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?Metabolism. 2016 Aug;65(8):1087-95. doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2. Metabolism. 2016. PMID: 26972222 Free PMC article. Review.
-
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18. Gastroenterology. 2019. PMID: 30660725 Free PMC article. Review.
-
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307. World J Gastroenterol. 2019. PMID: 30918425 Free PMC article. Review.
-
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004. Clin Liver Dis. 2018. PMID: 29128062 Review.
-
Liver fibrosis markers of nonalcoholic steatohepatitis.World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427. World J Gastroenterol. 2015. PMID: 26139988 Free PMC article. Review.
Cited by
-
Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring.Medicine (Baltimore). 2024 Oct 25;103(43):e40214. doi: 10.1097/MD.0000000000040214. Medicine (Baltimore). 2024. PMID: 39470560 Free PMC article.
-
Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).Sci Transl Med. 2023 Oct 4;15(716):eadi0759. doi: 10.1126/scitranslmed.adi0759. Epub 2023 Oct 4. Sci Transl Med. 2023. PMID: 37792957 Free PMC article. Review.
-
Association between novel inflammatory markers and non-alcoholic fatty liver disease: a cross-sectional study.Eur J Gastroenterol Hepatol. 2024 Feb 1;36(2):203-209. doi: 10.1097/MEG.0000000000002686. Epub 2023 Dec 1. Eur J Gastroenterol Hepatol. 2024. PMID: 38047735 Free PMC article.
-
Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application.Pharm Res. 2022 Aug;39(8):1789-1802. doi: 10.1007/s11095-022-03295-x. Epub 2022 May 24. Pharm Res. 2022. PMID: 35610402 Free PMC article.
-
Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis.Front Oncol. 2023 Aug 22;13:1198871. doi: 10.3389/fonc.2023.1198871. eCollection 2023. Front Oncol. 2023. PMID: 37675229 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical